Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

GLP-1 Use Among Young Children With Obesity in US Remains Rare but Is Rising Rapidly (opens in a new tab)

nyulangone.org · 2026-09-04

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 4Not checkedMen already at genetic risk for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity.View evidenceHide evidence

As stated7 percent added risk

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 4Not checkedThe study focused on the GLP1R gene as an indicator of GLP-1 agonist activity and compared GLP1R genes with genes found in men with androgenetic alopecia.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 4Not checkedPublished in the Journal of Investigative Dermatology online September 3, the study showed that higher GLP1R activity was more likely to be present in men who have androgenetic alopecia, and the 7 percent added risk remained after adjustment for hypertension, insulin resistance, and lowered testosterone levels.View evidenceHide evidence

As stated7 percent added risk

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 4Not checkedThe researchers said the findings provide the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia and suggested that future studies could explore screening and preventive combination treatments.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Integrative GWAS and Proteome-Wide Mendelian Randomization Identifies Novel Therapeutic Targets for Androgenetic Alopecia

2026 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.